Physician profile
Ersin Unal
NPI 1578825824
$14,098.15
in general payments reported to CMS, 2019-2025
67 companies · $4,909 in 2025
The $4,909 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.05 · 2020: $23.98 · 2021: $188 · 2022: $477 · 2023: $3,565 · 2024: $4,923 · 2025: $4,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,965.76 |
| Education | $431.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,745.01 | 2023-2025 | Erleada, Darzalex, Imbruvica |
| Novartis Pharmaceuticals Corporation | $1,256.68 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,074.76 | 2023-2025 | Enhertu, Imfinzi, Lynparza |
| Pfizer INC. | $962.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $641.47 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Merck Sharp & Dohme LLC | $565.75 | 2023-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $565.23 | 2022-2025 | Opdivo, Reblozyl, Opdualag |
| Eisai INC. | $535.91 | 2023-2025 | |
| Incyte Corporation | $501.22 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $498.48 | 2022-2025 | Enhertu |
| Lilly USA, LLC | $455.20 | 2022-2025 | Verzenio, Jaypirca |
| Genentech USA, INC. | $435.25 | 2020-2025 | Phesgo, Polivy, Venclexta |
| Celgene Corporation | $405.94 | 2023-2025 | Pomalyst, Reblozyl, Opdualag |
| Gilead Sciences, INC. | $315.93 | 2023-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $265.15 | 2022-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $241.74 | 2023-2025 | Xospata, Vyloy, Padcev |
| Glaxosmithkline, LLC. | $202.92 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Puma Biotechnology, INC. | $201.41 | 2023-2025 | |
| Pharmaessentia USA Corporation | $192.35 | 2023-2025 | Besremi |
| Array Biopharma INC | $191.28 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Aveo Pharmaceuticals, INC. | $167.82 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $145.61 | 2023-2025 | Ultomiris |
| Sobi, INC | $140.73 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $135.58 | 2024-2025 | Libtayo |
| Seagen INC. | $123.79 | 2023 | Adcetris, Tukysa |
| Stemline Therapeutics INC. | $118.81 | 2023-2025 | Orserdu, Elzonris |
| Adc Therapeutics America, INC. | $111.51 | 2023-2024 | |
| Emd Serono, INC. | $109.81 | 2024-2025 | |
| Tempus Ai, INC | $106.69 | 2024 | |
| Agios Pharmaceuticals, INC. | $105.35 | 2023-2024 | Pyrukynd |
| Genzyme Corporation | $90.42 | 2023-2025 | |
| Beone Medicines USA, INC. | $82.09 | 2025 | Brukinsa |
| Morphosys, US INC. | $72.22 | 2022-2024 | Monjuvi |
| Apellis Pharmaceuticals, INC. | $71.25 | 2023-2025 | Empaveli |
| Rigel Pharmaceuticals, INC. | $69.99 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Taiho Oncology, INC. | $65.93 | 2023-2024 | |
| Exelixis INC. | $65.13 | 2023-2025 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.82 | 2024-2025 | Gilotrif |
| Beigene USA, INC. | $61.88 | 2023 | Brukinsa |
| Amgen INC. | $61.53 | 2023 | Lumakras, Nplate, Vectibix |
| Azurity Pharmaceuticals, INC. | $59.89 | 2025 | Danziten |
| Mirati Therapeutics, INC. | $52.98 | 2023 | Krazati |
| Jazz Pharmaceuticals INC. | $48.31 | 2023-2025 | |
| Abbvie INC. | $46.78 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $46.31 | 2022-2023 | Somatuline Depot, Onivyde |
| Janssen Pharmaceuticals, INC | $43.40 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $43.04 | 2023-2024 | Pylarify |
| Karyopharm Therapeutics INC. | $42.37 | 2022-2024 | Xpovio |
| Boston Scientific Corporation | $37.28 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Ge Healthcare | $34.84 | 2025 | |
| Novocure INC. | $33.98 | 2025 | Optune Lua (Novottf-200t) |
| Sumitomo Pharma America, INC. | $33.83 | 2023 | Orgovyx |
| Syndax Pharmaceuticals, INC. | $32.60 | 2025 | |
| Geron Corporation | $31.94 | 2025 | Rytelo |
| Genmab U.S., INC. | $31.63 | 2025 | Epkinly |
| Fresenius Kabi USA, LLC | $27.24 | 2024 | |
| Springworks Therapeutics, INC. | $26.95 | 2025 | Ogsiveo |
| Immunocore Limited | $26.36 | 2024 | Kimmtrak |
| Pharmacosmos Therapeutics INC. | $25.35 | 2025 | Monoferric |
| Adaptive Biotechnologies Corporation | $22.95 | 2023 | Clonoseq |
| Kyowa Kirin, INC. | $21.79 | 2024 | Poteligeo |
| Blue Earth Diagnostics | $21.55 | 2024 | |
| Kite Pharma, INC. | $20.95 | 2025 | Yescarta |
| Sirtex Medical INC | $18.74 | 2024 | Sir-Spheres Microspheres |
| Dendreon Pharmaceuticals LLC | $15.63 | 2025 | Provenge |
| Deciphera Pharmaceuticals INC. | $14.52 | 2024 | Qinlock |
| Cumberland Pharmaceuticals, INC. | $13.20 | 2023 | Sancuso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ersin Unal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.